Supernus Pharmaceuticals: stockholders approve merger with Indivior

What happened

• On Oct 15, 2026 Supernus Pharmaceuticals, Inc. held a special meeting of its stockholders and reported that stockholders adopted the Merger Agreement among the Company, Indivior Pharmaceuticals Inc. and Artemis Merger Sub, Inc. Pursuant to the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Indivior.
• As of the close of business on Sep 4, 2026 there were 58,224,143 shares of common stock outstanding and entitled to vote. The Supernus Merger Proposal (Proposal 1) received 48,249,532 votes for, 235,601 votes against and 67,004 abstentions. A separate non-binding vote on executive compensation in connection with the Merger (Proposal 2) received 32,688,410 votes for, 15,847,350 votes against and 16,377 abstentions. The definitive proxy statement was filed Sep 11, 2026.

Key details

• Outstanding shares entitled to vote: 58,224,143 (as of Sep 4, 2026).
• Proposal 1 (adopt Merger Agreement): 48,249,532 for; 235,601 against; 67,004 abstain.
• Proposal 2 (non-binding approval of executive compensation): 32,688,410 for; 15,847,350 against; 16,377 abstain.
• The Merger Agreement parties: Supernus Pharmaceuticals, Indivior Pharmaceuticals Inc., and Artemis Merger Sub, Inc.

Why it may matter

• This Item 5.07 disclosure reports the submission of matters to a vote of security holders and provides the vote totals on the adoption of the Merger Agreement and on a non-binding compensation vote related to the Merger. The filing reports the outcomes and vote counts recorded at the special meeting.
• The filing does not show why the insider traded or why the company acted.